RBC Capital analyst Randall Stanicky noted that Allergan (AGN) does not use any specialty pharmacy, as the company confirmed in a press release earlier today. Endo's (ENDP) use of them is limited, with only a low single digit percentage of overall 2015 revenue flowing through independent specialty pharmacies, the analyst added. Stanicky also said Depomed's (DEPO) specialty pharmacy exposure is small. The comments from RBC come after a number of drugmakers' shares have declined in the wake of Citron Research's claim that Valeant (VRX) could have committed fraud regarding its relationship with specialty pharmacy Philidor RX.